Aurora Cannabis Inc.
CNSX : ACB
FRANKFURT : 21P
OTC PINK : PSNTF

May 13, 2015 12:12 ET

Aurora Signs Agreement with CanGenX BioTech Inc. for Pharmaceutical Type Production and Rapid Propagation to Increase Crop Yields

VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 13, 2015) - Aurora Cannabis Inc. (CSE:ACB)(FRANKFURT:21P)(WKN:A1C4WM)(OTC PINK:PSNTF) ("Aurora" or the "Company) is pleased to announce that the agreement to undertake plant tissue culture as the Company's production basis has been formalized with Dr. Geoff White of CanGenX BioTech Inc.

Plant tissue culture offers several distinct advantages over the traditional asexual propagation technique known as 'cloning'. With plant tissue culture, each plant is produced under completely sterile conditions ensuring all batches begin in a disease-free environment. These controlled conditions provide for massive scalability in predictable timeframes along with consistency, ensuring the integrity of future crops. In addition, unlike traditional cloning, plant tissue culture allows for faster propagation while utilizing fewer resources. This leads to greater production efficiencies and increased yields due to improved plant vigor and health. Plant tissue culture melds well with pharmaceutical type production as it incorporates Good Manufacturing Practices in every aspect of the process.

Dr. Jason Dyck, Board Director and head of Aurora's Research Council said, "Healthcare practitioners can be assured that plant tissue culture is just one of the many systems Aurora has implemented to ensure patients have access to safe, high quality standardized cannabis. The signing of the CanGenX BioTech contract confirms once again to our shareholders and industry stakeholders that the Company is committed in ensuring that the Aurora Standard is the Gold Standard throughout North America."

About Aurora Cannabis Inc.

Aurora's wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical marijuana pursuant to the Marihuana for Medical Purposes Regulations and operates a 55,200 square foot expandable state-of-the-art production facility in Alberta, Canada. Aurora's wholly-owned subsidiary, Australis Capital Inc., seeks to be an active participant in the U.S. Cannabis market. Aurora is trading on the Canadian Securities Exchange under the trading symbol "ACB".

On behalf of the Board of Directors,

AURORA CANNABIS INC.

Terry Booth, CEO

This news release contains statements about the Company's expectations regarding the agreement with CanGenX BioTech Inc. to establish a plant tissue culture program that is forward-looking in nature and, as a result, is subject to certain risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from the forward-looking statements. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Such factors include but are not limited to the Company's ability to realize the expected yields resulting from the plant tissue culture program in the amounts, quality or timeframe anticipated and other risks set out in the Company's management's discussion and analysis filed on SEDAR. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. We seek Safe Harbor.

Contact Information